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ABSTRACT 
Background: Albumin-based nanoparticles have been used as drug 
carriers to improve therapeutic effect. This study aimed to produce 
sulfasalazine (SSZ)-loaded bovine serum albumin (BSA) nanoparticles by 
desolvation technique and characterize their physical properties. Drug 
loading effect was also investigated.  
Methods: SSZ albumin nanoparticles were batch produced by desolvation 
technique and lyophilized. Physical characteristics of nanoparticles 
including size distribution, zeta potential and entrapment efficiency were 
studied.  
Results: Nanoparticles were spherical and typically 200–400 nm with low 
polydispersity (PDI). The zeta potentials of nanoparticles ranged from −21 
to −41 mV, which were attributed to BSA and SSZ. The highest actual drug 
loading was close to 0.5%w/w. The addition of 2% sucrose during 
lyophilization was essential to avoid cake collapse and the particle sizes 
increased slightly where their PDI values were low. Although the presence 
of sucrose led to a slight reduction in zeta potential, it had limited effect 
on zeta potential of the nanoparticles. The interactions between SSZ and 
formulation excipients were also confirmed with FTIR and DSC analyses.  
Conclusion: Desolvation technique produced stable sulfasalazine-loaded 
nanoparticles that can be administered parenterally. 
KEYWORDS: sulfasalazine; nanoparticle; albumin; physical property 
INTRODUCTION  
Sulfasalazine (SSZ) is a serine-threonine specific protein kinase 
activation inhibitor that inhibits 𝑥𝑥𝑐𝑐− cysteine/glutamate antiporter in order 
to reduce cellular glutathione level [1]. An induction of tumor cell death 
and an enhanced anti-proliferative effect were previously reported 
combining SSZ with other agents [1–3]. In a Phase 1 clinical study, an oral 
solid form of SSZ (marketed product) in combination with cisplatin was 
given to patients with advanced gastric cancer [4]. The trial data showed 
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that there was a reduction in CD44v-positive cancer cell population in the 
biopsy tissues in a small number of patients. However, the objective 
response of the trial was not achieved, as the blood concentration for SSZ 
did not reach the tumor cell killing level with current oral SSZ dose regime. 
Hence, developing a parenteral preparation consisting of SSZ that can 
achieve a blood level high enough will potentially enhance its therapeutic 
effect for this indication.  
There are several ways to deliver nanoparticle formulations, which 
include administration of the suspended nanoparticles via parenteral 
route. Nanoparticles can withstand physiological stresses, improve 
intracellular penetration of the cargo and enhance drug activity. They may 
be fabricated from either natural or synthetic polymers [5,6]. Albumin, a 
biopolymer, is an attractive material for the synthesis of nanoparticles. It 
is non-toxic, biodegradable and can be readily excreted from the body 
after drug release. Moreover, it has a reasonably long residence time in 
the bloodstream, and it may change the pharmacokinetic profile of the 
embedded drug [5]. Albumin-based nanoparticles can load various types 
of drugs [7,8]. The charged residues at their surfaces help to stabilize the 
nanoparticles and maintain particle dispersion [9]. Surface charge density 
and size of the nanoparticles are the factors that influence their biological 
fate [8]. These properties are governed by the materials and techniques 
used in the particle fabrication. Albumin nanoparticles can be produced 
by desolvation [10,11], emulsification [12] or thermal gelation [13]. One of 
the concerns for desolvation technique is producing a stable nanoparticle 
formulation with reproducible size [14]. Hence, the properties of albumin 
solutions have to be manipulated to control the nanoparticle synthesis 
[15,16]. The benefit of encapsulating drugs including SSZ into 
nanoparticles has been reported, however, so far no research has been 
done using bovine serum albumin (BSA) to deliver SSZ in a parenteral 
form. The current study will explore the desolvation conditions for the 
synthesis of SSZ-loaded nanoparticles. The effect of drug loading on the 
physical properties including size and zeta potential of the nanoparticles 
will also be examined. It is predicted that by using a water-soluble form of 
nano-carriers where SSZ molecules are protected in the hydrophobic 
pocket of BSA, the efficiency of drug delivery can be enhanced while the 
toxicity and side effects can be potentially reduced. 
MATERIALS AND METHODS 
Materials 
Sulfasalazine, bovine serum albumin and 8% aqueous glutaraldehyde 
(GTA) were purchased from Sigma-Aldrich (Missouri, USA). HPLC grade 
ethanol, potassium dihydrogen orthophosphate and disodium hydrogen 
phosphate were obtained from Fisher Scientific (Loughborough, UK). 
Sodium hydroxide pellets and sucrose were from BDH Chemicals (Poole, 
UK). Deionized water was used as diluent.  
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Preparation of Nanoparticles 
BSA nanoparticles were prepared using desolvation technique 
published previously [10] with modifications. BSA and SSZ powders were 
weighed (Mettler MT5 Balance, Columbus, USA) according to the 
compositions in Table 1. BSA powder was dissolved in 2 mL of 15 mM 
phosphate buffer (PB) pH 9 and then SSZ powder was dissolved in the BSA 
solution. The pH of the mixture was re-adjusted to pH 9 with sodium 
hydroxide solution. Sample was left to stir for 10 min at 800 rpm (Hanna 
HI-190M, Leighton, UK) under room temperature before adding  
8 mL of ethanol continuously at 1 mL/min using a P-1 Pharmacia pump 
(Uppsala, Sweden). Then 0.11 mL of 8% GTA was added and the suspension 
was left to stir for 18 h, followed by washing with deionized water for 3 
times with centrifugation (Beckman J2-21, Beckman Coulter, Indianapolis, 
USA) at 13,000 rpm for 30 min after each wash to purify the samples. The 
retrieved nanoparticles were re-dispersed in 8 mL of 2% sucrose solution 
except for one sample that was re-dispersed in same amount of water. All 
samples were frozen at −80 °C before they were lyophilized for 48 h 
(Martin Christ Alpha 1–2 LDplus, Osterode, Germany) under constant 
conditions, which were at 10 °C and 0.011 mbar.  
Table 1. Formulation compositions of the unloaded BSA and drug-loaded BSA nanoparticles.  
Material  Quantitative compositions 
Sulfasalazine (mg) - 1 2 3 2 2 
Albumin (mg) 100 100 100 100 100 100 
Glutaraldehyde (mL) 0.11 0.11 0.11 0.11 - 0.11 
2% sucrose (mL) 8 8 8 8 8 - 
Drug Calibration Plot and Encapsulation Efficiency Study  
A 50 µg/mL stock solution was prepared by dissolving SSZ powder in PB 
pH 9. Then the stock solution was diluted to prepare calibration standards 
(2–16 µg/mL). The drug levels were monitored by M501 Camspec UV 
spectrometer (Leeds, UK) at 359 nm, as this was the wavelength for 
maximum absorbance. Calibration plot showed a good linearity  
(R2 = 0.9998) with a calculated specific absorbance value of 631, which was 
close to the literature value (refer to Appendix Figure A1)[17]. The amount 
of un-entrapped drugs that were retrieved from the supernatants during 
sample purification process, (from Section “Preparation of 
Nanoparticles”) were tested twice. To calculate the encapsulation 
efficiency (%EE), the amount of drug found in the supernatant was 
subtracted from the amount that was initially added, which gave the 
amount of drug entrapped in the nanoparticles before converting into the 
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Particle Size Distribution and Zeta Potential 
The freshly prepared suspensions were diluted 200 times with water 
before measuring size and polydispersity index (PDI) by using Zetasizer 
Nano ZSP system (Malvern instrument, Cambridge, UK). Besides, 1 mg 
lyophilized nanoparticles was re-dispersed in 200 mL of the same medium 
to study the effect of lyophilization on size and zeta potential of the 
nanoparticles using the same equipment. The pH values of the samples 
after dilution were closed to the pH of blood (which is pH 7.4). 
Measurements were performed in triplicates at 25 °C. 
Morphological Analysis by Scanning Electron Microscopy (SEM) 
The freshly prepared sample was deposited on a carbon adhesive disc 
of the SEM stud. The samples were dried before being coated with a layer 
of platinum by using a sputter coater (Model: AGB7340, Agar Scientific, 
Essex, UK). The samples were visualized with a Hitachi SEM (Model:  
S-3000N, Tokyo, Japan) under vacuum at 5000 V and the images were 
acquired.  
Fourier-Transform Infrared (FTIR) Spectroscopy  
Fourier-transform IR analysis of the samples and powder specimens 
was performed. The FTRA spectra were obtained by using a Shimadzu 
IRAffinity-1S spectrometer (Shimadzu UK Ltd, Buckinghamshire, UK). The 
samples were scanned at the wavelengths between 550 and 4000 cm−1. The 
resolution of the scan was 4 cm−1 and 16 scans were recorded for each 
spectrum.  
Differential Scanning Calorimetry (DSC) 
Three to five mg of lyophilized sample was placed in a sealed hermetic 
aluminium pan before subjecting to a single heating cycle from 0 to 300 °C 
at 10 °C/min in a nitrogen atmosphere with a nitrogen flow rate of  
50 mL/min, and the thermograms were obtained by using DSC (Model: 
Q1000, TA Instrument, Ghent, Belgium). The equipment was calibrated 
and the settings were confirmed with indium standard.  
Preliminary Drug Release and Solubility Tests 
Ten mg of lyophilized form of drug-loaded nanoparticles (initial 2%w/w 
drug loading) were dispersed in 200 mL water. The samples were shaken 
at 25 °C in a water bath for 24 h to monitor the amount of drug release. 
The total fraction of drug release was calculated based on the actual 
amount of drug found in the nanoparticles (refer to Section “Drug 
Encapsulation Efficiency”). Furthermore, an excess amount of SSZ 
powder was added to 2 mL of BSA solution (water as diluent), the sample 
was then shaken at 25 °C for 24 h to determine the amount of drug 
dissolved, i.e., drug solubility. The samples for both tests were centrifuged 
to collect the supernatants, which were further filtered and diluted with 
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phosphate buffer before determining the drug levels by a UV spectrometer 
according to Section “Drug Calibration Plot and Encapsulation 
Efficiency Study”. Tests were performed twice. 
Statistical Analysis 
Statistical analysis was performed by SPSS software (version 25.0, SPSS 
Inc., Chicago, USA). The statistical tests included ANOVA and Paired t-test. 
They were used to examine the physicochemical properties of the 
nanoparticles such as particle size and zeta potential as well as the drug 
entrapment efficiency. A p-value of ≤0.05 was considered that the 
difference was statistically significant. 
RESULTS AND DISCUSSION 
Preparation of Nanoparticles 
Desolvation is a feasible technique that can produce albumin 
nanoparticles [10]. In this study, ethanol has been selected as the 
desolvation agent. The volume and flow rate of ethanol affect the size of 
the nanoparticles [15]. The ratio of sample to ethanol was kept at 1 to 4 and 
the flow rate was adjusted to 1 mL/min, as these conditions allowed the 
formation of BSA nanoparticles. It was noted that the BSA solutions turned 
cloudy after adding 5 mL of ethanol indicating supersaturation of BSA, and 
as a result, nucleation and nuclei growth by coagulation have enabled the 
particle formation.  
The sample’s pH is a critical factor that controls coagulation of the 
solvated BSA [15]. Changing sample’s pH alters the net charges on the 
protein surface [11]. BSA solution with pH that was adjusted to close to its 
isoelectric point (IEP ~4.7) readily aggregated to form large particles [18]. 
While at the pH above its IEP, negative charges were induced at the surface 
of the proteins and a smaller nanoparticle size was reported [11]. In the 
current study, pH 9 was chosen for the synthesis of nanoparticle as the 
drug bears a carboxylate on its structure that is readily ionized under this 
condition (Figure 1). After the addition of SSZ powder, pH of BSA solution 
dropped to ~6.6 as the dissolved SSZ species was acidic in nature and pH 
value of the sample had to be re-adjusted. Glutaraldehyde is the key cross-
linking agent.  
 
Figure 1. Chemical structure of sulfasalazine.  
 
Pharmaceutical Frontiers 6 of 15 
 
Pharm Front. 2019;1:e190006. https://doi.org/10.20900/pf20190006 
The amount of GTA can affect the physical properties such as size and 
surface charges of the nanoparticles [15]. The carbonyl groups of GTA 
react with the amino moieties (such as that found in lysine of BSA) via a 
nucleophilic reaction to form Schiff bases in the neutral to alkaline 
environment [19], thus preventing re-solvation of BSA molecules. In this 
study, 8.8 mg GTA per 100 mg BSA was used and the suspensions were 
stirred for 18 h to complete the reaction. This has led to nanoparticles with 
a narrow size distribution, which is stable in characteristics as discussed 
in the following sections.  
Drug Encapsulation Efficiency 
Entrapment efficiency was studied by varying the theoretical drug 
loading (TDL, also refer to as initial drug loading) from 1 to 3%w/w (mg 
SSZ per 100 mg BSA). The best drug encapsulation was obtained when 
1%w/w TDL was used (p = 0.152, F = 3.73 by ANOVA, Figure 2). The highest 
actual drug loading (ADL) was close to 0.5%w/w when 2%w/w TDL was 
used (p = 0.038, F = 11.89), and this was significantly higher than those 
loaded with 1%w/w TDL. The quenching of BSA fluorescence by SSZ has 
previously showed and accordingly, the drug molecules could bind to BSA 
subdomains and the binding constant was 3 × 10−6 M [20]. In this study, the 
quantities of drug used were between 2.5 × 10−6 M and 7.6 × 10−6 M. In 
addition, the reaction time was three folds less than previously reported 
[20]. Hence, a lower TDL and a longer reaction time can lead to a better 
drug encapsulation efficiency.  
 
Figure 2. Actual drug loading levels and encapsulation efficiency (%EE) values of the drug-loaded 
nanoparticles. Bars represent encapsulation efficiency and symbols (with the line) represent the actual drug 
loading. Note: initial drug loading is also referred to as theoretical drug loading (TDL) in the text. 
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Particle Size Distribution, Morphology and Zeta Potential 
Particle size distribution affects product quality and the behavior of 
nanoparticles in the biological system. In the current study, the 
nanoparticle sizes of all the samples were found to be within the 
nanometer range. They also exhibited a mono-modal size distribution and 
the PDI values were typically <0.3 (Figure 3 and refer to Appendix 
Figure A2). For the freshly prepared samples, an increase in TDL resulted 
in a larger particle size. The mean particle sizes of the nanoparticles 
ranged from 208 to 381 nm (p < 0.05, F = 145.07), and the sizes were 
significantly larger when TDL of 2%w/w or above were employed in the 
fabrication process. As dynamic light scattering technique detects 
variation in the scattered light intensity, the absorption and emission of 
labeled dyes or self-luminescent materials such as sulfasalazine may affect 
the measured DLS signals and thus, particle size of the sample. Geißler and 
co-workers reported a decrease of the correlation coefficient when a 
higher concentration of fluorescence dye was present in the nanoparticles 
[21]. According to the authors, the observed phenomenon was attributed 
to an increased absorption of the incident light that had resulted in a lesser 
coherent light scattering. In spite of the observed changes in the 
correlation functions, Geißler and co-workers demonstrated that there 
was an insignificant effect on the measured particle sizes of their labeled 
nanoparticles. In the current study, statistical analysis of the particle sizes 
for the freshly prepared nanoparticles as mentioned above showed that 
the size of drug-loaded nanoparticles (at 1%w/w TDL) was not significantly 
different from the unloaded nanoparticles. This has provided further 
evidence supporting that the application of DLS in a standard 
configuration is reliable even for fluorescent nanoparticles if their 
emission is reasonably low [21].  
A B 
  
Figure 3. Particle size, polydispersity index (PDI) and zeta potential values of the nanoparticles. (A) Bars 
represent the particle size (black or white bars) and zeta potential (grey bars) values. (B) Lines represent the 
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After lyophilization process, an increase in particle size of the 
nanoparticles was observed. The mean sizes ranged from 229 to 426 nm  
(p < 0.05, t = −8.785, the comparison was based on Paired t-test between the 
fresh and lyophilized samples). The freshly prepared samples had smaller 
PDI values than the lyophilized samples despite adding a sufficient 
quantity of sucrose [22]. In the absence of GTA and sucrose, the 
reconstituted suspensions had larger sizes between 699 and 688 nm, and 
their PDI values were high, which were 0.6 and 0.55, respectively. 
Collapsed cake structure was seen in the sucrose-free sample confirming 
that sucrose is an effective protectant during lyophilization process. 
Nanoparticles with spherical morphology and uniform particle size were 
observed by using a high resolution SEM, thus supporting the low PDI 
values reported above with DLS technique (Figure 4A). For the GTA-free 
sample, aggregates were seen (Figure 4B).  
A B 
  
Figure 4. Typical morphologies of nanoparticles viewed under high resolution by using a scanning electron 
microscopy (magnification 8000×). Drug-loaded nanoparticles prepared by using 2%w/w initial drug loading 
(A) with glutaraldehyde (left); (B) without glutaraldehyde (right), were used as specimens. 
Zeta potential measures the charges displaying at particle’s surface 
[23]. A larger zeta potential value indicates a greater repulsion amongst 
the particles leading to a better colloidal stability. In the current study, zeta 
potential values of the samples ranged from −24.8 to −36.3 mV. The 
samples were measured at the pH resembling the blood, which was the 
intended route for administration for this formulation. These values 
concur to the results reported previously (Figure 3A)[15]. The zeta 
potential values became significantly more negative after adding SSZ 
compared to those prepared without adding drug except for the sample 
that was prepared with 1%w/w TDL (p < 0.05). Although SSZ bound to the 
hydrophobic pockets of BSA molecules, its carboxylate group was ionized 
at neutral or alkaline solution. The presence of this ionized group has 
contributed extra charges to the drug-loaded nanoparticles. The measured 
zeta potential for nanoparticles without GTA was −21.0 mV and they 
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fluctuated (from −12 to −30 mV), as the desolvated BSA coacervates had 
not been cross-linked. Sucrose molecules interact with BSA by forming 
hydrogen bonds during the lyophilization process. As it is weakly acidic in 
nature, it can lower pH of the suspending medium and thus altering 
charge density of the nanoparticles. Comparing drug-loaded nanoparticles 
with and without sucrose that were prepared with 2%w/w TDL, the zeta 
potential values were slightly more negative for the latter but not 
significant (p > 0.05). This was partly because the pH of the samples was 
similar. Hence, adding sucrose has not compromised charge stabilization 
of the nanoparticles.  
FTIR Analysis  
Fourier transform infrared spectroscopy evaluates the chemical and 
conformational changes in the nanoparticles. Spectra of the nanoparticles 
with or without drug were similar (Figure 5). In protein infrared spectrum, 
the structural changes are presented by the shifts in certain characteristic 
bands (Table 2)[24]. Some of these bands were shifted in the nanoparticles 
when compared to pure BSA powder (e.g., Amide III by 16 cm−1) Moreover, 
the presence of SSZ in the drug-loaded nanoparticles shifted Amide II band 
(by 8 cm−1 when compared to blank nanoparticle). All the nanoparticles 
showed a slight decrease for CH2 bending to 1443 cm−1 except for the 
sample without sucrose added. This result indicates that an interaction has 
occurred between sucrose molecules and nanoparticles. 
 
Figure 5. Fourier transform infrared spectra for (a) drug, (b) sucrose, (c) BSA powder, (d) BSA 
nanoparticles without drug, (e) drug-loaded nanoparticles. The peaks of protein analyzed are (I) Amide A. 
(II) Amide B, (III) Amide I, (IV) Amide II, (V) CH2 bending and (VI) Amide III. 
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Table 2. Assigned protein bands for BSA and nanoparticles according to the FTIR spectra. 
Assigned band 
(cm−1) 





Amide A 3287 3279 3279 3279 
Amide B 2932 2932 2932 2932 
Amide I 1643 1643 1643 1643 
Amide II 1520 1543 1535 1535 
CH2 bending 1451 1443 1443 1451 
Amide III 1242 1258 1258 1258 
DSC Analysis  
Differential scanning calorimetry monitors the physical property of a 
substance by using a controlled temperature program. An endothermic 
peak for SSZ was seen just above 250 °C, corresponding to its melting point 
(Figure 6). Pure BSA and sucrose exhibited endothermic peaks at 216 and 
188 °C, respectively. Thermograms of drug-loaded nanoparticles only 
showed endothermic peak for BSA with the drug peak non-detectable, 
which suggested that the embedded drug was in an amorphous state. The 
interaction between SSZ and BSA was further evidenced by the shift of BSA 
bands as observed in FTIR analysis (Section “FTIR analysis”), confirming 
the change in their physicochemical properties (Table 2). The observed 
BSA endothermic peak corresponds to its thermal denaturation 
temperature. 
 
Figure 6. Thermograms as monitored by differential scanning calorimetry using standard mode. (a) Sucrose, 
(b) drug, (c) BSA, (d) BSA nanoparticles without drug and (e) drug-loaded nanoparticles (with 2%w/w initial 
drug loading). 
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Nanoparticles without drug exhibited a higher BSA endothermic peak 
(219.6 °C) than pure BSA powder. For drug-loaded nanoparticles, BSA peak 
has shifted to give a higher denaturation temperature (220.1 °C). Hence, 
the presence of drug has enhanced the thermal stability of the 
nanoparticles, as the key particle’s matrix was made of BSA. Lack of sugar 
in the drug-loaded nanoparticles shifted BSA endothermic peak to a lower 
temperature (185 °C), further confirming the role of sucrose in 
stabilization of albumin nanoparticles.  
Preliminary Drug Release and Solubility Data  
Sulfasalazine has a poor aqueous solubility, which is predicted to be 
0.0024 mg/mL [25]. Preliminary tests in the current study showed that the 
drug solubility increased to 1 mg/mL, confirming that SSZ molecules 
interact with BSA. The observed enhancement in drug solubilization is 
also partly due to BSA, which is a water-soluble protein. The result was 
supported by the changes seen in DSC and FTIR data as discussed above.  
The total fraction of drug release was 0.37 after placing the sample at 
25 °C for 24 h in dark. For paclitaxel-loaded albumin nanoparticles, the 
non-cross-linked particles showed a quicker disintegration profile than 
the cross-linked version [26]. The addition of 8.8 mg GTA in this study 
during the fabrication process has led to the nanoparticles resistant to 
disintegration. Hence, the amount of GTA and cross-linking time can be 
adjusted to modulate drug release. 
CONCLUSIONS 
Sulfasalazine-loaded BSA nanoparticles were prepared successfully by 
using the desolvation method. The nanoparticles were spherical in shape 
and the particle sizes ranged between 200 and 400 nm with low PDI values. 
In neutral pH environment, they exhibited negative zeta potential values 
that were attributed to both BSA and SSZ. The lyophilized nanoparticles 
can be easily re-suspended under this condition and these formulations 
can be administered via the parenteral route.  
In this study, the effect of drug loading was investigated, and this factor 
is found to alter sizes and zeta potential values of the nanoparticles. The 
maximum drug encapsulation efficiency was 28% when a low TDL was 
used. The highest ADL was close to 0.5%w/w. The success of drug 
entrapment was also indicated by the peak shifts in both thermal and 
infrared analyses. Addition of 2% sucrose added to the nanoparticle 
formulation has avoided cake collapse but the particle sizes has increased 
slightly while the PDI values remain low. Thus, lyophilization cycle 
condition can to be further optimized. Adding sucrose also led to a slight 
reduction in zeta potential values without exerting a detrimental effect on 
surface charge of the nanoparticles. Nonetheless, the interaction between 
BSA and SZZ has provided positive features of the nanoparticles with a 
higher thermal denaturation temperature. In summary, desolvation 
technique used in this study has produced stable nanoparticle 
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formulations that are loaded with sulfasalazine. These nanoparticles can 
be administered as a water-soluble injection with an enhancement in drug 
solubility. 
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APPENDIX  
 
Figure A1. Calibration plot of sulfasalazine. Note: UV measurements of the calibration standards were also 
performed after storage in dark for at least 24 h and repeated after 5 days. The results were the same, 
demonstrating the reproducibility of the experimental outcomes.  
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Figure A2. An example of particle size distribution data obtained from DLS analysis.  
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